You are here

Humira

AbbVie, already famous for its Humira strategy, forms another 'patent wall' around Imbruvica: report

AbbVie, already famous for its Humira strategy, forms another 'patent wall' around Imbruvica: report

Fierce Pharma

Flag link:

AbbVie's Humira on Steroids (Literally) Treats Rheumatoid Arthritis Better Than the Original

AbbVie's Humira on Steroids (Literally) Treats Rheumatoid Arthritis Better Than the Original

Motley Fool

clinical trials

monoclonal antibodies

Flag link:

AbbVie's Humira defense may keep prices high, but it's still legal, judge rules

AbbVie's Humira defense may keep prices high, but it's still legal, judge rules

Fierce Pharma

Flag link:

AbbVie touts Humira defense strategy abroad as a positive sign for forthcoming U.S. battle

AbbVie touts Humira defense strategy abroad as a positive sign for forthcoming U.S. battle

Fierce Pharma

Flag link:

AbbVie's plan to replace Humira is ahead of schedule

AbbVie's plan to replace Humira is ahead of schedule

BioPharma Dive

Flag link:

Should AbbVie break up Allergan? If it wants to make up for Humira, then yes, analyst says

Should AbbVie break up Allergan? If it wants to make up for Humira, then yes, analyst says

Fierce Pharma

Flag link:

Roche's Ocrevus, GSK's Dovato ads top November TV spending charts—behind Humira, of course

Roche's Ocrevus, GSK's Dovato ads top November TV spending charts—behind Humira, of course

Fierce Pharma

Flag link:

UCB posts more supportive data from Humira rival bimekizumab

UCB posts more supportive data from Humira rival bimekizumab

Pharmaforum

Flag link:

FDA approves latest Humira near-copy, as dozens of biosimilars head for market

FDA approves latest Humira near-copy, as dozens of biosimilars head for market

Pharmaforum

Flag link:

Eli Lilly's Taltz extends its head-to-head Humira beat with 52-week psoriatic arthritis data

Eli Lilly's Taltz extends its head-to-head Humira beat with 52-week psoriatic arthritis data

Fierce Pharma

psoriatic arthritis

Flag link:

3 Most Important Takeaways From AbbVie's Q3 Results

3 Most Important Takeaways From AbbVie's Q3 Results

Motley Fool

Flag link:

Novartis’ Cosentyx Narrowly Misses Beating Out AbbVie’s Humira in Arthritis Trial

Novartis’ Cosentyx Narrowly Misses Beating Out AbbVie’s Humira in Arthritis Trial

BioSpace

psoriatic arthritis

Flag link:

AbbVie, Gilead and Allergan 3-peat with September's top pharma TV spending

AbbVie, Gilead and Allergan 3-peat with September's top pharma TV spending

Fierce Pharma

Gilead Sciences

Flag link:

Humira, Rituxan top list of U.S. drugs with biggest price increases -report

Humira, Rituxan top list of U.S. drugs with biggest price increases -report

Yahoo/Reuters

Flag link:

Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report

Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report

Fierce Pharma

Bristol-Myers Squibb

Flag link:

AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since Humira

AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since Humira

Motley Fool

Flag link:

These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024

These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024

Yahoo/Motley Fool

Bristol-Myers Squibb

Flag link:

5 Things You Need to Know From AbbVie's Q2 Earnings Results

5 Things You Need to Know From AbbVie's Q2 Earnings Results

Motley Fool

Flag link:

AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib

AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib

Fierce Pharma

rheumatoid arthritis

Flag link:

FDA-approved Humira copycat from Merck, Samsung Bioepis will wait 4 years to launch

FDA-approved Humira copycat from Merck, Samsung Bioepis will wait 4 years to launch

Endpoints

Samsung Bioepis

Flag link:

Pages